iRadimed Corporation (NASDAQ:IRMD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of iRadimed Corporation (NASDAQ:IRMD) have been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $120.00.

A number of analysts have issued reports on IRMD shares. Weiss Ratings lowered iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 3rd. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

Hedge Funds Weigh In On iRadimed

Several large investors have recently bought and sold shares of the stock. Rice Hall James & Associates LLC acquired a new stake in iRadimed in the 2nd quarter worth $2,909,000. Hsbc Holdings PLC bought a new position in shares of iRadimed during the 2nd quarter worth about $1,130,000. Bridge City Capital LLC raised its position in shares of iRadimed by 19.4% during the fourth quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock valued at $6,893,000 after buying an additional 11,509 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new stake in shares of iRadimed in the fourth quarter valued at about $595,000. Finally, Punch & Associates Investment Management Inc. bought a new stake in shares of iRadimed in the second quarter valued at about $1,911,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Price Performance

IRMD stock opened at $86.59 on Friday. iRadimed has a 52-week low of $67.84 and a 52-week high of $107.90. The company has a 50-day moving average of $92.42 and a two-hundred day moving average of $93.72. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 48.37 and a beta of 0.89.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities analysts expect that iRadimed will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.